EGFR and non-small cell lung carcinoma: We included trials that met the following criteria in our meta-analysis: (1) Patients with completely resected, early-stage (stage I to III) pathological confirmed NSCLC; (2) Phase 2/3 RCTs comparing adjuvant EGFR-TKIs with chemotherapy or placebo; (3) Primary endpoints such as OS or DFS were reported; (4) Safety and adverse events (AEs) of EGFR-TKI or chemotherapy were evaluated in these trials.